leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 07:21:51 - browse：34

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Fauci’s Covid grilling leads GOP to weigh foreign research rules

WSS

Doctors find melanoma drugs effective against rare brain cancer

JPM 2024: Verve Therapeutics looks to mainstream genome editing

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Sanders adds drug shortage policies to pandemic preparedness bill

Generative AI mines health records to identify patients’ social needs

How Medicaid coverage policies for immigrants impact new moms

knowledge

leisure time

entertainment

Jerome Adams on the need for new antivirals for Covid

Caregivers of transplant patients call for more support, training

How one medical school became remarkably diverse

STAT Virtual Event: The State of Biosimilars: What to Watch

State Dept. review finds Biden bears some blame for Afghanistan failures

New England Journal of Medicine addresses racist history, slavery

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

HHS names first

ChatGPT in medicine: STAT answers readers' burning questions

HHS names first

focus

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Cosmetics set for new safety regulation. Why the industry is on board

DeSantis can now import cheaper drugs. But will Biden get credit?

Key House panel plots a new health care package

https://cbu01.alicdn.com/img/ibank/2016/283/224/3704422382_696119772.220x220xz.jpg

knowledge

hotspot

hotspot

focus